Company Overview - Entrada Therapeutics focuses on treating devastating diseases with intracellular targets [2] - The company is advancing multiple clinical programs for Duchenne muscular dystrophy (DMD) in the U.K., EU, and U.S. [2] - By 2026, Entrada expects to have four clinical stage programs in its DMD franchise [2] Clinical Progress - Entrada highlighted significant progress across its EEV portfolio for neuromuscular and ocular diseases [2] - The company is also making progress in its partnership for myotonic dystrophy type 1 with Vertex, specifically with the program VX-670 [2] - The year is anticipated to have several value-driving catalysts for the company [2]

Summary of Entrada Therapeutics FY Conference Call Company Overview - **Company**: Entrada Therapeutics (NasdaqGM:TRDA) - **Focus**: Treating debilitating diseases with intracellular targets, particularly in neuromuscular and ocular diseases - **Key Programs**: Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) in partnership with Vertex Key Points and Arguments Clinical Programs and Pipeline - Entrada is advancing multiple clinical programs for DMD, with expectations to have four clinical-stage programs by the end of 2026 [1][2] - The company has made significant progress in its EEV (endosomal escape vehicle) portfolio, particularly for neuromuscular diseases [3][4] - Upcoming data releases include: - ENTR-601-44 program: Top-line data expected in Q2 2026 - ENTR-601-45 program: First cohort data expected in mid-2026 - ENTR-601-50 program: Data expected by year-end 2026 [6][7][8] Financial Position - As of the end of 2025, Entrada had approximately $296 million in cash, providing a runway into Q3 2027 [10][43] Differentiation and Competitive Advantage - Entrada's approach utilizes a differentiated endosomal escape vehicle platform, achieving a 25-fold improvement in endosomal escape compared to competitors [11][18] - The company emphasizes low drug doses with high concentrations, reducing the risk of exposure and antibody response [12][29] - The strategy includes running clinical studies outside the U.S. to gather data for FDA discussions on accelerated approval [13][16] DMD and DM1 Programs - The DMD program aims for double-digit dystrophin production, which is crucial for efficacy [14] - The partnership with Vertex for the DM1 program includes significant financial incentives, with a total of $485 million in milestones [34] - The DM1 program is expected to complete enrollment and dosing by mid-2026 [35] Expansion into Ocular Diseases - Entrada announced its expansion into inherited retinal diseases, specifically targeting Usher syndrome type 2A, with a candidate named ENTR-801 [36][38] - This program addresses a significant unmet need, with approximately 15,000 patients in the U.S. and Europe lacking therapeutic options [37] Future Growth and Strategy - Entrada plans to continue expanding its pipeline into other intracellular targets and ocular diseases, with a focus on optimizing oligonucleotides and exploring new therapeutic areas [39][41] - The company aims to establish itself as a leader in the DMD space, with a substantial patient population of over 14,000 in the U.S. and Europe [33] Important but Overlooked Content - The company’s strategy includes a focus on safety, with no treatment-related adverse events reported in healthy volunteer studies [22] - The ability to achieve clinically relevant exon skipping and measurable protein production for at least 90 days in the ocular program is a significant milestone [38] - Entrada's approach to kidney safety is noteworthy, as it limits the risk of toxicity while increasing efficacy [29] This summary encapsulates the critical aspects of Entrada Therapeutics' conference call, highlighting its strategic direction, clinical advancements, and financial health.

-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 – -- Expects to initiate global Phase 1/2 MAD clinical study of ENTR-601-50 by the end of 2026 and to submit global regulatory applications for ENTR-601-51 in 2026 – -- Expands pipeline with selection of ENTR-801 as first clinical candidate in ocular diseases for the treatment of Usher syndrome type 2A and expects to nominate second clinical candidate in 2026 – -- Cash ...

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET). A live webcast will be available on the Presentations portion of Entrada’s Investor Relations website at https://ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event. About ...

Entrada Therapeutics ( TRDA ) reported a 3Q25 GAAP EPS loss of -$1.06 along with a revenue figure of $1.6 million. Since earnings on November 6th, the stock is up about 25%. In the report, there was a pretty sharp declineI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciatio ...

Financial Performance - Collaboration revenue decreased significantly to $1.614 million in Q3 2025 from $19.570 million in Q3 2024, a decline of $17.956 million[118]. - Net loss for Q3 2025 was $44.134 million, compared to a net loss of $14.032 million in Q3 2024, an increase in loss of $30.102 million[118]. - For the nine months ended September 30, 2025, collaboration revenue was $24.1 million, a significant decrease of $149.3 million from $173.4 million in 2024, primarily due to fewer costs incurred for VX-670[126]. - Net loss for the nine months ended September 30, 2025, was $104.6 million, compared to a net income of $64.5 million for the same period in 2024, a decline of $169.1 million[125]. Expenses - Research and development expenses increased to $38.361 million in Q3 2025 from $31.257 million in Q3 2024, an increase of $7.104 million[118]. - General and administrative expenses rose to $10.304 million in Q3 2025 compared to $9.971 million in Q3 2024, an increase of $333,000[118]. - Total operating expenses for Q3 2025 were $48.665 million, up from $41.228 million in Q3 2024, reflecting an increase of $7.437 million[118]. - Total research and development expenses for the nine months ended September 30, 2025, were $108.3 million, an increase of $16.4 million from $91.9 million in 2024, driven by higher direct research costs[127]. Cash and Funding - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $326.8 million, sufficient to fund operations into Q3 2027[99]. - The company has raised over $850.0 million in gross proceeds from stock sales and collaborations since inception, with $326.8 million in cash and marketable securities as of September 30, 2025[140]. - The company plans to file a new shelf registration statement to replace the prior one that will expire on November 7, 2025, allowing for future equity offerings[142]. - The company anticipates significant future funding requirements due to ongoing research and development expenses[152]. Strategic Developments - The company has two product candidates, ENTR-601-44 and ENTR-601-45, in clinical development for Duchenne muscular dystrophy (DMD)[99]. - The company expects to report data from the first cohort of the ENTR-601-44 study in Q2 2026 and from the first patient cohort of ENTR-601-45 in mid-2026[101]. - The company anticipates filing for EU regulatory clearance for ENTR-601-50 in the second half of 2026 and for ENTR-601-51 in 2026[100]. - Vertex Pharmaceuticals is on track to complete enrollment and dosing in the VX-670 trial in the first half of 2026[105]. Workforce and Operational Changes - A strategic plan approved on April 29, 2025, led to a workforce reduction of approximately 20%, incurring charges of $1.9 million[158]. - The company has entered into contracts with CROs and third-party manufacturers for preclinical research, which are cancellable upon prior written notice[156]. - The company remains classified as an "emerging growth company" and a "smaller reporting company," allowing it to take advantage of reduced reporting requirements[159][162]. Other Financial Metrics - Total interest and other income decreased to $3.6 million for the three months ended September 30, 2025, down from $5.8 million in 2024, reflecting changes in interest earned from debt securities and a decrease in marketable securities[123]. - For the nine months ended September 30, 2025, the company reported a net cash used in operating activities of $96.3 million, driven by a net loss of $104.6 million[145]. - The company generated $87.7 million from investing activities for the nine months ended September 30, 2025, primarily from $212.1 million in maturities of marketable securities[147]. - Net cash provided by financing activities was $0.7 million for the nine months ended September 30, 2025, compared to $101.6 million for the same period in 2024[149][150].

Financial Position - Cash, cash equivalents, and marketable securities were $326.8 million as of September 30, 2025, down from $420.0 million as of December 31, 2024[6]. - The expected cash runway has been extended into Q3 2027, supported by the current cash position[1]. Revenue and Expenses - Collaboration revenue for Q3 2025 was $1.6 million, a significant decrease from $19.6 million in Q3 2024, primarily due to the completion of collaboration research activities related to VX-670[7]. - Research and development (R&D) expenses increased to $38.4 million in Q3 2025 from $31.3 million in Q3 2024, driven by costs associated with DMD programs and higher personnel costs[10]. - General and administrative (G&A) expenses rose to $10.3 million in Q3 2025 from $10.0 million in Q3 2024, mainly due to increased personnel costs[11]. - Total operating expenses for Q3 2025 were $48.7 million, compared to $41.2 million in Q3 2024[17]. - Net loss for Q3 2025 was $(44.1) million, compared to a net loss of $(14.0) million for the same period in 2024[11]. Clinical Development - The company is on track to report data from the first patient cohort of ELEVATE-44-201 in Q2 2026 and ELEVATE-45-201 in mid-2026[2]. - The company expects to initiate a Phase 1b MAD clinical study of ENTR-601-44 in the U.S. in the first half of 2026[8]. - The company filed for regulatory authorization in the U.K. to initiate ELEVATE-50-201, a global Phase 1/2 MAD clinical study of ENTR-601-50[1].

Core Insights - Entrada Therapeutics is advancing its clinical programs for Duchenne muscular dystrophy (DMD) and expects significant data releases in 2026, including results from the ELEVATE-44-201 and ELEVATE-45-201 studies [2][6] - The company reported a cash position of $327 million as of September 30, 2025, which is expected to fund operations into Q3 2027 [1][7] - Collaboration revenue decreased significantly to $1.6 million in Q3 2025 from $19.6 million in Q3 2024, primarily due to the completion of research activities related to VX-670 [8] Financial Performance - Cash, cash equivalents, and marketable securities were $326.8 million as of September 30, 2025, down from $420.0 million as of December 31, 2024, due to operational funding [7] - Research and development (R&D) expenses increased to $38.4 million in Q3 2025 from $31.3 million in Q3 2024, driven by costs associated with DMD programs and higher personnel expenses [9] - General and administrative (G&A) expenses rose slightly to $10.3 million in Q3 2025 from $10.0 million in Q3 2024, mainly due to increased personnel costs [10] Clinical Development Pipeline - Entrada is advancing multiple clinical programs for DMD, with three clinical-stage programs expected by year-end 2025 [3] - The company has completed enrollment for Cohort 1 of the ELEVATE-44-201 study and is on track to report data in Q2 2026 [6] - The first patient has been dosed in the ELEVATE-45-201 study, with data expected in mid-2026 [5][6] Preclinical Pipeline Expansion - Positive preclinical data has been generated for ocular and metabolic disease programs, with two ocular programs advancing to lead optimization [4] Regulatory and Future Plans - The company has filed for regulatory authorization in the U.K. to initiate the ELEVATE-50-201 study and plans to submit applications in the EU in the second half of 2026 [5][6]

Core Insights - Entrada Therapeutics, Inc. will participate in two upcoming investor conferences, highlighting its engagement with the investment community [1][2][3] Group 1: Upcoming Events - The CEO, Dipal Doshi, will present at the Jefferies Global Healthcare Conference in London on November 18, 2025, at 5:00 p.m. GMT [2] - Dipal Doshi will also participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025, at 12:55 p.m. ET in Miami, FL [3] - Live webcasts of these events will be available on the Investor Relations section of the company's website, with replays accessible for 90 days post-event [3] Group 2: Company Overview - Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing a new class of medicines targeting intracellular mechanisms previously deemed inaccessible [4] - The company's proprietary Endosomal Escape Vehicle (EEV™) therapeutics aim to enhance the intracellular delivery of various therapeutics, improving the therapeutic index [4] - Entrada is advancing a development portfolio that includes RNA- and protein-based programs for treating neuromuscular and ocular diseases, with lead programs targeting Duchenne muscular dystrophy [4]

Company Overview - Entrada Therapeutics is a clinical stage biotech company focused on transforming patients' lives through innovative therapies [2] - The company has developed a proprietary technology platform known as Endosomal Escape Vehicles (EEVs), which enhances the delivery of therapeutics [2] Technology Platform - EEVs enable access to intracellular targets, which is crucial as approximately 75% of disease targets are intracellular in nature [3] - The unique chemistry of EEVs facilitates improved therapeutic delivery, making it a significant advancement in the biotech field [3] Lead Indications - Entrada's two lead indications are focused on Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1), highlighting the company's commitment to addressing serious genetic disorders [2]